LINX vs Fundoplication

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Oxford

About this trial

Reflux disease can severely impact upon quality-of-life and lead to complications, including ulceration of the oesophagus. It is often controlled with self-help measures and medication. However, sometimes surgery is recommended. The current standard surgical treatment is called a fundoplication. This operation is carried out through keyhole (laparoscopic) surgery, and tightens the lower oesophagus to prevent reflux. Fundoplication is very safe and improves the quality-of-life of most patients. However, many patients have gas bloating, difficulty swallowing and recurrence of their reflux symptoms. As an alternative, some surgeons use a device called LINX, using a keyhole procedure. LINX is a magnetic device that wraps around the lower oesophagus to prevent reflux. Studies suggest that LINX may cause fewer complications, with a similar improvement in quality-of-life. However, there is a need for better evidence to compare LINX with fundoplication in the surgical treatment of reflux disease. GOLF is a multi-centre study designed which to determine if LINX achieves similar reflux control and improves symptoms compared to fundoplication. GOLF measures: (1) quality of life,(2) surgical complications, including need for additional treatment, (3) financial cost-effectiveness and (4) objectively measure the presence of acid that has refluxed into the lower oesophagus. GOLF aims randomise 460 patients to receive fundoplication or the LINX device. It will be conducted across at least 16 UK and 7 European specialist surgical centres. All participants will be followed up at 6 weeks, 6, 12 and 24 months to assess which treatment offers the best results after surgery. A quality assurance programme within participating centres will ensure that procedures are completed to a high-quality standard. Study results will incorporate a patient and public involvement programme, which will inform national and international guidelines for the surgical treatment of reflux disease.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 years and above

Willing and able to give informed consent

Patients with GORD insufficiently controlled by medical therapy or intolerance to medical therapy being considered for anti-reflux surgery

Symptomatic and objectively defined GORD; endoscopy with appearances or biopsies consistent with reflux oesophagitis, or 24-hour pH study or BRAVO test of the oesophagus consistent with GORD

Disqualifiers

Unsuitable for surgical intervention due to medical conditions precluding general anaesthesia

Suspected or known allergies to titanium, stainless steel, nickel, or ferrous materials

Previous anti-reflux or gastric surgery

Previous or planned neurosurgical intervention

Trial design

Design model

Parallel

Treatments tested in this trial

  • Laparoscopic or robotic LINX procedure

    Procedure/Surgery

    Participants randomised to laparoscopic or robotic magnetic sphincter augmentation (LINX procedure) will receive surgical treatment under general anaesthesia, with placement of the LINX device around the distal oesophagus. The LINX device comprises titanium beads with magnets in the centre.

  • Laparoscopic or robotic fundoplication

    Procedure/Surgery

    Participants randomised to laparoscopic or robotic fundoplication will receive surgical treatment for managing GORD including a total or partial fundic wrap behind or in front of the distal oesophagus and gastro-oesophageal junction.

Treatment groups

460 Participants
are divided into 2 treatment groups
Group A: Laparoscopic or robotic fundoplicationActive comparator 1 intervention
Group B: Laparoscopic or robotic LINX procedureExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Symptomatic GORD and health-related quality of life (HRQL) assessed using the GORD-HRQL questionnaire

Time frame
24 months following surgery

Secondary outcomes

1

Prevalence of gas bloating measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire

Time frame
24 months postoperatively
2

Prevalence of inability to belch measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire

Time frame
24 months postoperatively
3

Prevalence of symptomatic GORD, inability to belch and gas bloating measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire

Time frame
6 weeks, 6 and 12 months after surgery
4

Severity of dysphagia and regurgitation measured using participant-reported outcomes/GORD-HRQL questionnaire

Time frame
6 weeks, 6, 12 and 24 months postoperatively

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Oxford

Lead sponsor

King's College London

Collaborator

Imperial College London

Collaborator

Oxford University Hospitals NHS Trust

Collaborator

Guy's and St Thomas' NHS Foundation Trust

Collaborator

University of Bristol

Collaborator

University of Southampton

Collaborator